Jazz Pharmaceuticals plc (JAZZ) Investment Research Dashboard
About Jazz Pharmaceuticals plc (JAZZ) stock analysis
Get live JAZZ stock price $255.43, comprehensive Jazz Pharmaceuticals plc stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time JAZZ stock data and investment insights.
Loading chart data...
Investment Score
A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.
Score unavailable for this asset.
0-39
Defensive posture
40-54
Mixed / wait for confirmation
55-69
Constructive setup
70-100
Attractive zone
Total Score
Value
Cheapness vs fundamentals and cash generation
Quality
Durability of profitability and balance sheet
Momentum
Price trend strength and persistence
Company Overview
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopat...
Company Information
- CEO
- Renee D. Gala
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2890
Contact Information
- Website
- https://www.jazzpharma.com
- Address
- Waterloo Exchange
- Country
- IE
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Listed on major US exchange (NASDAQ) providing liquidity and transparency
✓ Valuation metrics suggest potential value opportunity (P/E: 19.9)
✓ Lower volatility stock (Beta: 0.32) may provide portfolio stability
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Jazz Pharmaceuticals plc shareholders
- ⚠Market volatility can significantly impact stock price, especially for mid-cap stocks
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Jazz Pharmaceuticals plc
- ⚠Investors should consider how Jazz Pharmaceuticals plc fits within their overall portfolio allocation
Market Cap
16.05B
P/E Ratio (TTM)
19.86
Beta
0.32
Data Sources & Methodology
Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.
Related Stocks
Compare JAZZ with peer companies:
- Price
- $128.00+1.83% (1D)
- Market cap
- 9.40B
- Price
- $238.37-1.09% (1D)
- Market cap
- 12.27B
- Price
- $15.63+0.71% (1D)
- Market cap
- 4.42B
- Price
- $80.62-0.15% (1D)
- Market cap
- 10.03B
- Price
- $81.48-0.55% (1D)
- Market cap
- 9.66B
- Price
- $551.25+1.24% (1D)
- Market cap
- 12.71B
- Price
- $90.00+0.00% (1D)
- Market cap
- 6.83B
- Price
- $123.96+0.00% (1D)
- Market cap
- 9.13B
- Price
- $11.57+0.70% (1D)
- Market cap
- 197.91M
- Price
- $106.13+3.95% (1D)
- Market cap
- 7.28B
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.
Healthcare (1D)
72/100 ⭐⭐⭐⭐⭐
- Overall
- -0.1%
- NYSE
- -0.1%
- NASDAQ
- -0.1%
| Sector | 1D | 1W | 1M | P/E | Score |
|---|---|---|---|---|---|
| Consumer Defensive | +1.3% | +3.3% | +2.2% | 29.2 | 88/100⭐⭐⭐⭐⭐ |
| Financial Services | -0.1% | +0.9% | +2.0% | 19.3 | 86/100⭐⭐⭐⭐⭐ |
| Communication Services | +0.4% | -1.6% | +2.0% | 22.2 | 74/100⭐⭐⭐⭐⭐ |
| Healthcare | -0.1% | +0.5% | +0.8% | 23.5 | 72/100⭐⭐⭐⭐⭐ |
| Basic Materials | -0.7% | +0.1% | -1.3% | 24.9 | 60/100⭐⭐⭐⭐ |
| Energy | -0.4% | -2.0% | -2.4% | 19.4 | 51/100⭐⭐⭐ |
| Utilities | -1.5% | -0.5% | -4.9% | 25.4 | 40/100⭐⭐⭐ |
| Real Estate | -1.6% | -1.1% | -3.5% | 29.4 | 36/100⭐⭐ |
| Industrials | -0.4% | -0.5% | -10.7% | 30.5 | 19/100⭐ |
| Consumer Cyclical | -0.3% | -2.3% | -6.5% | 43.1 | 17/100⭐ |
| Technology | -1.9% | -4.0% | -9.4% | 41.9 | 7/100⭐ |
Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-28.